Zymeworks
Business Services · Canada · 201-500 Employees
View Company Info for Free
Overview
Headquarters
114 4th Ave E Suite 800, Vancouver, Brit...Phone Number
(604) 678-1388Website
www.zymeworks.comRevenue
$37.1 MillionStock Symbol
ZYMEIndustry
About Zymeworks
Zymeworks Org Chart
Is Zymeworks your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Zymeworks had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Zymeworks has new funding data
Check out if Zymeworks is spiking on competitors!
Earning: See what the market has to say on Zymeworks recently announced quarterly report
Website visits: Recent activity has been detected on your website
Zymeworks, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Zymeworks has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Zymeworks launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Zymeworks
Recommended Actions
Reach out to Masked Content who joined Zymeworks as Masked Content
Find 2 more new buyers
Compare Similar Companies to Zymeworks
Compare insights from companies similar to Zymeworks, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zymeworks is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Zymeworks is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Zymeworks.
Zymeworks financials insights
Gather financial insights about Zymeworks, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Multiple Rounds
$22.3M
Multiple Rounds
$34.4M
Series A
$61.5M
Stock Offering
$63.6M
Stock Offering
$97.8M
Stock Offering
$201.3M
Stock Offering
$320.8M
Zymeworks Tech Stack
A closer look at the technologies used by Zymeworks
Most Recent Scoops
Zymeworks News & Media
Zymeworks Completes Acquisition of Theravance Biopharma
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks’ strategy to build a diversified revenue-generating biotecZymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zymeworks Inc. (ZYME) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:50 PM EDTCompany ParticipantsKenneth Galbraith - Chairman...Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab
Zymeworks (NASDAQ:ZYME) shares climbed nearly 4. 0% in pre-market trading as investors positioned themselves ahead of an important U.Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will participate in the following upcoming investor conferences:
Top Business Services Companies
Top companies in Australia by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Zymeworks
Zymeworks Inc. is a global biotechnology company focused on developing, managing, and commercializing innovative biotherapeutics for the treatment of cancer, autoimmune disorders, and other serious diseases with significant unmet medical needs. The company combines proprietary antibody engineering technologies with a strategic healthcare asset mana... Read More


